MedTrace Logo

Study to Evaluate an Influenza Vaccine Candidate

NCT00540228 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1006

Last updated 2019-06-14

Study results available
· View outcomes & findings →

Summary

In order to find the formulation leading to a maximal increase of the immune response while maintaining an acceptable safety profile, this study is designed to evaluate the immunogenicity, safety and reactogenicity of the different formulations of GSK Biologicals' influenza vaccine administered in adults aged 18-64 years.

Conditions

Interventions

BIOLOGICAL

Influenza Vaccine GSK1247446A - 4 different formulations

Single dose, Intramuscular injection

BIOLOGICAL

Fluarix™

Single dose, Intramuscular injection

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-10-05
Primary Completion
2008-05-08
Completion
2008-05-08

Countries

  • France
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00540228 on ClinicalTrials.gov